Jeffrey Kim, Slingshot Biosciences
July 22, 2021 07:00 AM EDTUpdated July 26, 06:56 AM
Financing
Startups

From cel­list to syn­thet­ic cell-ist: Jef­frey Kim scores $23M to reimag­ine blood tests, cell ther­a­py

Nicole DeFeudis

Editor

It wasn’t al­ways Jef­frey Kim’s am­bi­tion to launch a biotech. In fact, af­ter grad­u­at­ing with his bach­e­lor’s de­gree in mol­e­c­u­lar bi­ol­o­gy from Prince­ton Uni­ver­si­ty, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: CEO of Unit­ed­Health in­sur­ance unit shot and killed in New York in what po­lice call ‘a brazen, tar­get­ed ...

Blue­bird and Ver­tex's sick­le cell gene ther­a­pies to kick off new Med­ic­aid ac­cess mod­el

Lil­ly beats No­vo in bell­wether head-to-head weight loss study

As 23andMe strug­gles, an­oth­er ge­net­ic test­ing com­pa­ny bets on drug dis­cov­ery

Mod­er­na CEO de­fends pan­dem­ic prep ef­forts with crit­ics set to en­ter Trump’s ad­min­is­tra­tion

Trade group tells FDA that semaglu­tide is not too 'com­plex' for com­pound­ing

A service from the Financial Times